Want to see GB:GDR full AI Analyst Report?
Genedrive (GDR) AI Stock Analysis
Genedrive
(LSE:GDR)
The overall score is constrained by very weak financial performance—persistent large operating losses, equity erosion, and heavy cash burn—despite some revenue traction and deleveraging, which together create a high-risk foundation. Technicals are moderately constructive, with the price above key moving averages and neutral momentum indicators, providing a near-term positive offset but not enough to overcome the underlying financial strain. Valuation adds limited support because the negative P/E and lack of dividend mean the investment case rests largely on speculative future turnaround rather than current fundamentals.
Genedrive (GDR) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 15.65M
- Dividend Yield
- ―
- Average Volume (3M)
- 3.43M
- Price to Earnings (P/E)
- -0.9
- Beta (1Y)
- -0.90
- Revenue Growth
- 65.60%
- EPS Growth
- 74.84%
- Country
- UK
- Employees
- 43
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Genedrive Business Overview & Revenue Model
Company Description
Genedrive Plc, a molecular diagnostics firm established in Manchester, UK, in 2000 (and known as Epistem Holdings Plc until its name change in July 2016), focuses on developing and commercializing innovative point-of-care diagnostic platforms. These...
How the Company Makes Money
Genedrive makes money primarily through the sale of its molecular diagnostics platform and the associated recurring consumables used to run tests. Key revenue streams typically include: (1) instrument sales or placements of the Genedrive device to he...
Genedrive Financial Statement Overview
Summary
Revenue is growing quickly and gross profit has turned positive, but the company remains deeply loss-making with a £5.4M EBIT loss in 2025, shrinking equity, and severe ongoing cash burn of about -£5.1M from operations, indicating a very high-risk financial profile.
Income Statement
35NegativeBalance Sheet
45NeutralCash Flow
25Negative| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.07M | 764.00K | 501.00K | 55.00K | 49.00K | 687.00K |
| Gross Profit | 898.00K | 764.00K | 254.00K | -199.00K | -3.82M | -3.82M |
| EBITDA | -5.58M | -5.36M | -7.49M | -5.70M | -5.37M | -1.37M |
| Net Income | -5.34M | -5.23M | -7.08M | -5.15M | -4.67M | -691.00K |
Balance Sheet | ||||||
| Total Assets | 1.75M | 2.81M | 6.80M | 4.51M | 6.62M | 4.88M |
| Cash, Cash Equivalents and Short-Term Investments | 387.00K | 1.18M | 5.19M | 2.60M | 4.59M | 2.57M |
| Total Debt | 500.00K | 0 | 19.00K | 241.00K | 16.00K | 119.00K |
| Total Liabilities | 2.17M | 1.38M | 1.44M | 2.47M | 1.01M | 1.28M |
| Stockholders Equity | -415.00K | 1.44M | 5.36M | 2.04M | 5.61M | 3.59M |
Cash Flow | ||||||
| Free Cash Flow | -3.90M | -5.12M | -3.80M | -3.83M | -4.67M | -5.29M |
| Operating Cash Flow | -3.89M | -5.10M | -3.77M | -3.78M | -4.61M | -5.18M |
| Investing Cash Flow | -10.00K | -23.00K | 1,000 | -37.00K | 45.00K | 33.00K |
| Financing Cash Flow | 2.19M | 1.12M | 6.36M | 1.82M | 6.58M | -456.00K |
Genedrive Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:GDR, the sentiment is Negative. The current price of 0.97 is below the 20-day moving average (MA) of 1.05, below the 50-day MA of 1.18, and below the 200-day MA of 1.12, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 32.90 is Neutral, neither overbought nor oversold. The STOCH value of 23.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:GDR.
Genedrive Peers Comparison
Overall Rating
GB:EKF64Neutral
GB:ONT59Neutral- GB:GDR49Neutral
GB:ABDX46Neutral
GB:RENX44Neutral
GB:APTA37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:EKF | 64Neutral | GBP 100.14M | 40.69 | 3.58% | ― | 2.26% | -57.04% |
| GB:ONT | 59Neutral | GBP 2.12B | -16.75 | -27.36% | ― | 14.80% | 16.88% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:GDR | 49Neutral | GBP 15.25M | -0.89 | -1044.57% | ― | 65.60% | 74.84% |
| GB:ABDX | 46Neutral | GBP 22.75M | -16.36 | -34.31% | ― | 30.42% | 43.16% |
| GB:RENX | 44Neutral | GBP 36.54M | -3.53 | 675.00% | ― | ― | ― |
| GB:APTA | 37Underperform | GBP 9.88M | -9.50 | -46.61% | ― | 28.35% | 57.14% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:GDR | Genedrive plc | 0.97 | -0.01 | -0.71% | |
| GB:EKF | EKF Diagnostics Holdings | 23.60 | -2.40 | -9.23% | |
| GB:RENX | Renalytix Plc OTC | 5.55 | -1.60 | -22.38% | |
| GB:ABDX | Abingdon Health PLC | 9.00 | 1.75 | 24.14% | |
| GB:APTA | Aptamer Group Plc | 0.28 | -0.52 | -64.38% | |
| GB:ONT | Oxford Nanopore Technologies PLC | 210.40 | 76.70 | 57.37% |
Genedrive Corporate Events
Genedrive strengthens board with Graham Cole CBE as new chair
PositiveGenedrive plc, the Manchester-headquartered AIM-listed point-of-care pharmacogenetic testing specialist, has appointed Graham Cole CBE as Chair and independent Non-Executive Director with immediate effect, bringing over 40 years of leadership experie...
Genedrive lifts revenues as NHS and international uptake of rapid genetic tests builds
PositiveGenedrive reported unaudited FY26 income of about £1.4 million, up from roughly £1.0 million in FY25, reflecting growing adoption of its MT-RNR1 and CYP2C19 tests in the UK and abroad, with around one quarter of revenue now generated intern...
Genedrive Wins Ministerial Backing as NHS Expands Rapid Pharmacogenetic Testing
PositiveGenedrive has gained high-profile validation for its MT-RNR1 ID Kit after UK Health Minister Preet Kaur Gill cited rapid pharmacogenetic testing for antibiotic-induced hearing loss in newborns as a powerful, practical example of personalised medicine...
Genedrive launches board shake-up as chairman Ian Gilham steps down
NeutralGenedrive plc, headquartered in Manchester, develops and commercialises precision pharmacogenetic tests such as the Genedrive CYP2C19 ID Kit for stroke patients and the Genedrive MT-RNR1 ID Kit for newborns, with a focus on embedding UK-developed poi...
Genedrive expands CYP2C19 diagnostics with Thermo Fisher lab collaboration
PositiveGenedrive has signed a collaboration agreement with Thermo Fisher Scientific to develop the Genedrive CYP2C19 HT Kit, a high-throughput pharmacogenetic in vitro diagnostic test for use on Thermo Fisher’s QuantStudio 5 Dx PCR platform, targeting...
Genedrive’s MT-RNR1 Test Adopted as Routine Neonatal Service at Manchester NHS Trust
PositiveGenedrive plc said Manchester University NHS Foundation Trust has moved the Genedrive MT-RNR1 ID Kit, which screens newborns for a genetic variant linked to aminoglycoside-induced hearing loss, into business-as-usual clinical service across its three...
Genedrive Secures £0.76m R&D Tax Credit to Support Expansion of Point-of-Care Genetics
PositiveGenedrive plc, a Manchester-headquartered pharmacogenetic diagnostics company focused on point-of-care tests for personalised prescribing, has built a portfolio that includes two CE-IVD approved and NICE-recommended assays deployed in NHS settings. T...
Genedrive Reports No Change in Share Option Scheme Balances in Latest Block Listing Return
PositiveGenedrive plc has confirmed its latest six‑monthly block listing return, reporting no changes in the number of securities available under its 2007 Share Option Scheme, 2017 Share Option Scheme and Unapproved Share Option Scheme for the period t...
Genedrive Reports No Share Issuance in Latest Block Listing Return
PositiveGenedrive plc has reported its latest six-monthly block listing return, confirming that no new shares were issued or allotted under its 2007 Share Option Scheme, 2017 Share Option Scheme, or Unapproved Share Option Scheme for the period from 1 Decemb...
Genedrive reshapes board as major shareholder joins and long-serving chairman prepares exit
PositiveGenedrive has strengthened its governance by appointing major shareholder David Nugent, who holds more than a quarter of the company’s shares and recently acted as a cornerstone investor in its February equity financing, as a non-executive dire...
Genedrive Test Adopted as Routine Neonatal Service at Sussex NHS Trust
PositiveGenedrive plc said University Hospitals Sussex NHS Foundation Trust has moved its Genedrive MT-RNR1 ID kit for preventing antibiotic-induced hearing loss in neonatal intensive care units to a Business as Usual clinical service from 1 May 2026. The tr...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: May 15, 2026